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ABSTRACT 
Background: Potentially lethal cardiac channelopathies/cardiomyopathies may underlie a 
substantial portion of sudden unexplained death in the young (SUDY).  The whole exome 
molecular autopsy (WEMA) represents the latest approach to postmortem genetic testing for 
SUDY.   However, proper variant adjudication in the setting of SUDY can be challenging.  
Methods: From January 2012 through December 2013, 25 consecutive cases of SUDY aged 
from 1-40 years (average age at death 27 ± 5.7 years; 13 white, 12 black) from Cook County, 
Illinois, were referred following a negative (n=16) or equivocal (n=9) conventional autopsy. A 
WEMA with analysis of 99 sudden death-susceptibility genes was performed.  The predicted 
pathogenicity of ultra-rare, non-synonymous variants (NSVs) was determined using the 
American College of Medical Genetics (ACMG) guidelines. 
Results: Overall, 27 ultra-rare NSVs were seen in 16/25 (64%) SUDY victims. Among black 
individuals, 9/12 (75%) had an ultra-rare NSV compared with 7/13 (54%) white individuals. Of 
the 27 variants, 10 were considered “pathogenic (P)” or “likely pathogenic (LP)” in 7/25 (28%) 
individuals in accordance with the ACMG guidelines. P / LP variants were identified in 5/16 
(31%) of autopsy-negative cases and in 2/6 (33%) SUDY victims with equivocal findings of 
cardiomyopathy.  Overall, 6 P/LP variants in 4/25 (16%) cases were congruent with the 
phenotypical findings at autopsy and therefore considered “clinically actionable”.  
Conclusions: WEMA with gene-specific surveillance is an effective approach for the detection 
of potential pathogenic variants in SUDY cases.  However, systematic variant adjudication is 
crucial to ensure accurate and proper care for surviving family members. 
KEY WORDS: Genetics, Sudden Death, Channelopathies, Cardiomyopathies 
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CLINICAL PERSPECTIVE 
What is new?  
 The first population-based, case-series study involving the whole exome 
sequencing-based cardiac channelopathy/cardiomyopathy gene specific molecular 
autopsy of sudden unexplained death in the young (SUDY) cases within the 
United States. 
 
What are the clinical implications?  
 While the ACMG guidelines are useful, careful evaluation of the decedent’s 
autopsy findings and/or pre-mortem clinical phenotype remains critical before 
adjudicating a variant as the definitive cause of death.  
 The goal of these investigative studies is to provide closure to families 
surrounding the loss of their loved one, b t perhaps the only thing worse than no 
answer, is to give a false answer prematurely. 
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INTRODUCTION 
Sudden cardiac death is a major world-wide public health burden with an estimated annual 
incidence ranging from 180,000 to 450,000 
1
 in the United States and as many as 3.7 million 
deaths globally 
2
. The majority of these deaths are due to coronary artery disease among the 
elderly 
3
. However, approximately 2,000 to 5,000 young people between 1 to 35 years of age die 
suddenly each year in the United States 
4
. For many of these sudden deaths in the young, a 
comprehensive medico-legal investigation including a conventional autopsy examination 
elucidates a clear cause of death. However, in up to 40% of these cases, gross and microscopic 
inspection of the heart and other organs fails to reveal a definite cardiac/non-cardiac etiology
5
, 
and are categorized as autopsy negative sudden unexplained death in the young (SUDY). 
Potentially lethal and heritable cardiac channelopathies like long QT syndrome (LQTS), 
catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada syndrome (BrS), 
are associated typically with grossly and histologically normal hearts and may account for a 
significant portion of SUDY. Additionally, heritable cardiomyopathies, including hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic cardiomyopathy 
(ACM), may present with a mild structural phenotype that could escape detection at autopsy. 
Together, these genetic heart diseases may be the underlying etiology for a significant percentage 
of SUDY cases.  
Recently, guidelines for autopsy investigations of SUDY cases stipulate procurement and 
retention of tissue suitable for DNA extraction as a class I recommendation and advise that 
postmortem genetic testing (i.e. the molecular autopsy) be considered as the new standard of care 
in the decedent’s evaluation 6-8. With at least 99 sudden death-susceptibility genes to date, post-
mortem genetic testing with whole exome sequencing (WES) and targeted gene analysis 
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represents a cost- and time-effective approach for performing the molecular autopsy. While there 
is increasing evidence to support the use of a whole exome molecular autopsy (WEMA) 
5, 9-15
, 
standardization of the procedure for characterizing putative pathogenic mutations is crucial to 
enable proper counseling of surviving family members and accurate publishing for scientific 
progress. Recently, the American College of Medical Genetics (ACMG) has provided guidelines 
for the interpretation of sequence variants 
16
 which may be helpful in delineating the predicted 
pathogenicity of variants identified by WEMA in SUDY cases.   
Here, we describe a cohort of 25 unrelated SUDY victims referred consecutively by the 
Office of the Medical Examiner, Cook County, Illinois. We performed a WEMA to determine the 
spectrum and prevalence or ultra-rare, nonsynonymous variants (NSVs) within sudden death-
susceptibility genes and demonstrate use of both the ACMG guidelines and the necropsy-derived 
phenotype data for proper variant adjudication.  
MATERIALS AND METHODS: 
The data, analytical methods, and study materials will not be made available to other researchers 
for the purposes of reproducing the results or replicating the procedure.  
Study Subjects 
From January 2012 to December 2013, 25 consecutive, unrelated SUDY cases were referred to 
the Windland Smith Rice Sudden Death Genomics Laboratory at the Mayo Clinic in Rochester, 
Minnesota, to undergo WEMA following Mayo Clinic IRB approval. All 25 cases underwent a 
comprehensive autopsy by the Office of the Medical Examiner from Cook County, Illinois. 
Enrollment criteria required sudden death of an individual between the ages of 1 and 40 years of 
age which remained unexplained or equivocal following a comprehensive autopsy. 
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Control Population 
973 European white control exomes (509 females, 464 males) from the ICR1000 UK exome 
series and the 1958 Birth Cohort study were included for a case:control subset analysis of genetic 
variation amidst these 99 genes between Caucasian decedents and these controls..
17
 As 
previously reported, exome sequencing was performed using the Illumina TruSeq and Illumina 
instruments.
17
 
DNA Isolation  
Genomic DNA was isolated from autopsy whole blood or frozen tissue using the Gentra 
Puregene Blood Kit (Qiagen, Maryland, US) following the manufacturer’s protocol.  
Whole Exome Next-Generation DNA Sequencing  
Genomic DNA samples were submitted to Mayo Clinic’s Advanced Genomics Technology 
Center for WES. The Bravo liquid handler and Aligent’s protocol was used to prepare paired-end 
libraries, and DNA was fragmented usi g a Covaris E210 sonicator. Agencourt AMPure SPRI 
beads were used to purify the constructs. SureSelect forward and Agilent SureSelect ILM Pre-
Capture Indexing reverse primers were used to enrich the DNA fragment libraries, which were 
analyzed with Agilent Bioanalyzer DNA 1000 chip. 
Exome capture was performed with the SureSelect XT Human All Exon V5 plus UTR 
Target Enrichment System (Agilent, Santa Clara, California). Dynal Dynabeads MyOne 
Streptavidin T1 captured the DNA:RNA hypbrids, and Agencourt Ampure XZP beads eluted 
DNA from the beads, which were amplified with Agilent Sure Select Post-Capture Indexing 
forward and Index PCR reverse primers. Sequencing of the exome libraries was completed with 
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Illumina HiSeq 2000 platform (San Diego, California) and TruSeq SBS sequencing kit V3 
reagents. 
Variant Filtering and Pathogenicity Assessment 
Following WES, variants were filtered using Qiagen’s Ingenuity® Variant Analysis™ software 
(Qiagen Bioinformatics, Redwood City, California). Variants were included only if they met the 
following filtering parameters: 1) had a high quality score (read depth > 10 reads, call quality > 
20, genotype quality > 20, and present in genes outside the top 1% of exonically variable genes 
and top 5% of exonically variable 100 base windows), 2) were NSVs (i.e. missense, nonsense, 
frameshift insertion/deletion [INDEL], in-frame INDEL, or splice error), and 3) met our  rarity 
threshold (minor allele frequency [MAF] ≤ 0.00005 in any ethnic group within Exome 
Aggregation Consortium [ExAC, n=60,706]
18
, 1,000 Genome Project [1KG, n=1,094]
19
, and the 
National Heart, Lung and Blood Institute Grand Opportunity Exome Sequencing Project [ESP, 
n=6,503] databases). Variants meeting the above criteria underwent a further gene-specific 
surveillance for all known cardiac channelopathy- , cardiomyopathy-, and sudden unexplained 
death in epilepsy (SUDEP)-susceptibility genes (N=99, Supplemental Table 1).  
The ACMG guidelines for the interpretation of sequence variants were used to classify 
identified variants as pathogenic (P), likely pathogenic (LP), or variant of uncertain significance 
(VUS) 
16
.  To be considered “clinically actionable”, the variant had to meet ACMG guideline 
criteria for a P or LP variant designation and be congruent with the presence/absence of disease-
gene suggested autopsy findings.   Here in, we consider a “clinically actionable” variant as a LP 
or P variant that should immediately prompt the physician to perform mutation-specific cascade 
genetic testing besides the standard cardiology clinical evaluation in all first-degree relatives of 
the deceased.  Further, among those relatives who test positive for the implicated variant, 
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periodic re-assessment of potential disease manifestation related to the identified disease-
susceptibility variant should be performed.  
Candidate disease-causing variants identified through WEMA were confirmed in the 
decedents’ genomic DNA using standard polymerase chain reaction (PCR) and Sanger 
sequencing methods.  PCR primers, conditions, and sequencing methods are available upon 
request. 
Statistical Analysis 
Fisher’s exact tests were performed to determine statistical significance between two groups.  A 
p<0.05 was considered to be significant.  
 
RESULTS: 
Sudden Unexplained Death in the Young Cohort 
The demographics for the 25 SUDY cases are summarized in Table 1. The average age at death 
was 27 ± 5.7 years. There were 17 males (68%) and 8 (32%) females. Thirteen (52%) cases were 
white and 12 (48%) were black. Sixteen (64%) cases were autopsy negative and 9 (36%) cases 
had equivocal findings or inconclusive cardiac abnormalities with 6 (24%) having equivocal 
findings for a possible cardiomyopathy. The 25 SUDY victims died during the following 
circumstances: unwitnessed (10; 40%), sleep (9; 36%), nonspecific (3; 12%) and exertion or 
auditory trigger (3; 12%). Eleven (44%) SUDY cases had a personal history of either illicit drug 
use (24%) or mental illness (20%). A prior history of arrhythmia or syncope was noted in 2 (8%) 
cases. No cases had a known family history of arrhythmia, syncope, seizure, or cardiac arrest.  
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Yield of Ultra Rare-Non-Synonymous Variants (NSVs) in Sudden Death-Susceptibility 
Genes 
Following WEMA, we identified 27 ultra-rare (MAF < 0.00005), NSVs within the 99 sudden 
death-susceptibility genes in 16/25 (64%) individuals overall including 9/12 (75%) black and 
7/13 (54%) white decedents (Figure 1 and Table 2).  Compared to the 54% yield observed in 
white cases, ultra-rare NSVs were identified in 281/973 (28.9%, p=0.064) European white 
controls (Figure 2). Interestingly, 4/13 (30.8%) white SUD cases hosted multiple ultra-rare 
NSVs amidst these 99 genes versus 43/973 (4.4%, p=0.002) of the European controls (Figure 
2).  Of the 27 NSVs identified, 4 (p.R783H-MYH7, p.L567Q-SCN5A, p.Y462S-RYR2, and 
p.N4763S-RYR2) were present in “major” genes (i.e. strong evidence for disease association) for 
cardiac channelopathies and cardiomyopathies (KCNQ1, KCNH2, SCN5A, RYR2, MYH7, and 
MYBPC3) and 23 variants were in “minor” genes (i.e. limited evidence genes) (Table 2 and 
Figure 3).  None of the variants were identified within any of the three SUDEP-susceptibility 
genes (KCNA1, SCN1A, and SCN8A). 
Variant Adjudication with ACMG Guidelines 
Of the 27 ultra-rare NSVs, 10 NSVs (37%) were classified as pathogenic (P) variants or likely 
pathogenic (LP) variants based on the ACMG guideline criteria (Figure 1 and Table 2).  These 
10 NSVs were found in 7/25 (28%) individuals [5/13 (38%) white and 2/12 (17%) black].  
Compared with the white SUDY cases, 36/973 (3.7%) white controls hosted an ultra-rare NSV in 
> 1 of the 99 genes that would be graded as either a LP or P variant (p=0.000098).  Multiple LP 
or P variants were identified in 2/13 (15.4%) of the white sudden death victims versus 2/973 
(0.21%, p=0.00094) white controls (Figure 2).  P or LP variants were identified in 5/16 (31%) 
autopsy negative SUDY victims and in 2/6 (33%) SUDY victims that had an equivocal finding 
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of cardiomyopathy at autopsy.  There were 9 (36%) decedents who each hosted an ultra-rare 
variant of uncertain significance (VUS).  These VUSs are potentially informative given their 
ultra-rare status.  However, all 17 VUSs identified occurred in so called “minor” genes where the 
strength of evidence for disease association is limited (Figure 3).  Furthermore, only 5 of the 17 
VUS matched the phenotype at autopsy.  Although there appears to be genotype-phenotype 
concordance potentially, these variants could not be considered the underlying cause of death 
until further evidence for pathogenicity is satisfied with either functional validation studies or 
other criteria in the ACMG guidelines. Twelve VUSs were discordant with the phenotype 
observed at autopsy and therefore were dismissed as likely benign (Figure 3). 
Clinically Actionable Variants 
The ACMG has proposed that the use of the term “likely pathogenic” (and therefore also 
pathogenic) should mean that the variant of interest has a > 90% certainty of being disease-
causing 
16
. However, some NSVs identified through WES that meet the ACMG criteria for a P or 
LP designation, may not be consistent with the autopsy findings for the SUDY.   Of the 10 P/LP 
variants that were identified, 6 variants (p.R350Q-DES, p.R783H-MYH7, p.N4763S-RYR2, 
p.L567Q-SCN5A, p.V2736fs-TTN, and p.D22167fs-TTN) identified in 4/28 (14.3%) were 
congruent with the SUDY’s phenotype at autopsy and therefore deemed “clinically actionable” 
(Table 2 and Figure 3).   
The remaining 4 P/LP variants (p.Q1289X-DSP, p.K942X-MYH6, c.903+1 G>A-NEBL, 
and p.Y462S-RYR2) were not congruent (Table 2 and Figure 3) with autopsy findings.  
Although p.Q1289X-DSP, p.K942X-MYH6, c.903+1 G>A-NEBL, all satisfy the ACMG 
guideline criteria for P or LP designation based on being an “ultra-rare” and null variant (i.e. 
nonsense or splice-error), these variants in cardiomyopathy-associated genes were identified in 
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SUDY victims with no autopsy findings suggestive of a structurally abnormal heart.  Therefore, 
these variants may require additional lines of evidence prior to assigning them as being disease-
causing and relevant to surviving family members.  The p.Y462S-RYR2 variant was identified in 
a patient with autopsy findings consistent with HCM.  RYR2 mutations cause CPVT, a 
structurally normal heart-associated arrhythmia syndrome. This SUDY case also hosted a desmin 
(p.R350Q-DES) LP variant that would be consistent with his autopsy findings and most likely 
represents the pathogenic basis for the decedent’s sudden death.     
Case Summaries for SUDY Victims with a Clinically Actionable Variant 
Overall, 4/25 (16%) of the SUDY cases hosted at least one “clinically actionable” variant.  A 14-
year-old white male (Case 1, Table 2) who experienced an exertion-related autopsy negative 
sudden death, hosted a p.L567Q-SCN5A pathogenic variant and a p.N4763S-RYR2 likely 
pathogenic variant.   SCN5A encodes a voltage-gated cardiac sodium channel, and mutations in 
the gene have been associated with LQT3 
20
 and BrS1 
21
. Electrophysiological studies of the 
p.L567Q-SCN5A mutation have demonstrated a significant effect on sodium channel 
inactivation
22
, and the patients with this specific mutation are particularly prone to sudden death 
23
.   RYR2 gene mutations cause CPVT, a structurally normal heart associated arrhythmia 
syndrome that often manifests during exertion.   
A 27-year-old black female (Case 9, Table 2) who collapsed suddenly with seizure-like 
activity, had a p.R783H-MYH7 pathogenic variant and a p.V27236fs-TTN likely pathogenic 
variant. She had a history of a cardiac blood clot four years prior to death and her autopsy was 
equivocal for ischemic cardiomyopathy. The MYH7 gene is associated with familial HCM and 
DCM. Although the p.R783H variant results in a conservative amino acid substitution, this 
specific variant has been observed previously in two individuals with cardiomyopathy 
24
. TTN 
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frameshift mutations have been associated with DCM.  The TTN frame-shift variant identified in 
this SUDY case localizes to the sequence segment encoding for the A-band region of the protein, 
where such frameshift mutations are overrepresented in cases of DCM compared to controls 
25
. 
A 28-year-old white male (Case 15, Table 2), found dead in bed, hosted both a p.R350Q-
DES and a p.Y462S-RYR2 likely pathogenic variant. He had history of arrhythmias and was 
scheduled for cardioversion later that year. Additionally, his autopsy was equivocal for HCM 
with microscopic findings of myocyte hypertrophy and gross findings of an enlarged tricuspid 
valve with abnormal chordae, enlarged chambers, left ventricle hypertrophy, and fusion of right 
and non-coronary cusps of the aortic valve. His heart was enlarged, weighing 610g. His mother 
was diagnosed previously with HCM.  DES -encoded desmin is a class III intermediate filament 
specific to muscle cells. Mutations in desmin have been associated with HCM, DCM, 
myofibrillar myopathy, and sudden death 
26-29
.  RYR2 encodes the cardiac ryanodine receptor 
found in the sarcoplasmic reticulum of cardiac muscle. The receptor facilitates calcium release 
that is crucial for cardiac contraction.  
A 36-year-old white female (Case 23, Table 2), who was found unresponsive in bed, 
hosted a p.D22167fs-TTN frameshift variant designated as likely pathogenic. She had history of 
heart murmur of an unknown type.  Although originally considered autopsy negative, 
microscopic findings at autopsy included mild to moderate interstitial fibrosis as well as myocyte 
hypertrophy. The mutation results in a frameshift mutation within the region encoding for the A-
band portion of the TTN protein where frame-shift mutations are overrepresented in DCM cases 
when compared to controls 
25
.  
DISCUSSION 
Since providing the first ever proof-of-principle case report of a WES-based comprehensive 
molecular autopsy of a previously healthy 16-year-old SUDY victim, where we identified a 
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pathogenic MYH7 mutation 
30
,  the utility of the whole exome molecular autopsy (WEMA) has 
been recognized increasingly as an efficient and cost-effective method for comprehensive post-
mortem genetic evaluation of SUDY cases 
5, 9-15
. 
Here, we present the first population-based study involving WEMA of SUDY cases 
within the United States.  Using WES and a gene-specific analysis involving 99 cardiac 
channelopathy-, cardiomyopathy-, and SUDEP-associated genes, we identified an ultra-rare 
(MAF < 0.00005; 1 in 20,000 alleles), amino acid altering variant in a sudden death-
susceptibility gene in 54% of our white and 75% of our black SUDY victims.   
In 2016, Bagnall and colleagues reported on the genetic analysis of 59 cardiac 
channelopathy/cardiomyopathy genes in a similar SUDY cohort of 113 cases from Australia or 
New Zealand
5
.  Using a MAF < 0.1% (i.e. 1 in 1000 alleles), 27% of their cases hosted what they 
termed a ‘clinically relevant’, ‘pathogenic’ or ‘likely pathogenic’ cardiac gene mutation.  Of the 
36 ‘clinically relevant’ variants identified, 30 had a MAF < 0.00005 (the threshold used in our 
study).  Thus, 6 of the variants identified would not have been considered to be potentially 
disease-causing using our more stringent MAF cut-off.  In fact, 4 of these variants have a higher 
prevalence in ExAC (1 in 500 to 1 in 1000 subjects) than the estimated disease prevalence (for 
example, 1 in 2000 for LQTS) that they would be associated with. 
While both studies support the utility of WEMA to identify potential sudden death-
causing variants within sudden death-susceptibility genes, the challenge of the WES-based 
molecular autopsy does not lie in the identification of variants, but rather, in the adjudication of 
their predicted pathogenicity. Accurate variant classification is crucial to enable proper 
counseling of surviving family members and accurate publishing for scientific progress.  
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Erroneously or prematurely adjudicating ambiguous variants as pathogenic has the 
potential to harm patients and their families. Tragically, this became a reality for one family 
described by Ackerman et al., as they dealt with the disastrous consequences of unnecessary 
treatment based on an erroneously interpreted variant in KCNQ1 
29
. Our group and others have 
estimated previously that as much as 10% of the variants published as LQTS-associated 
mutations may be classified incorrectly
31, 32
. This number is likely to be higher when accounting 
for all sudden death genes, as a recent study has indicated that as many as 30% of all disease-
causing genetic variants in the literature may have been reported incorrectly
33
. 
In order to assist in the interpretation of identified variants, the ACMG guidelines provide 
a framework for variant classification by incorporating a variety of weighted factors that lead to 
a final delineation of pathogenic (P), likely pathogenic (LP), benign, or  variant of uncertain 
significance (VUS) 
16
. Using strict criteria, variants are assessed for “very strong” (i.e. a null 
variant), “strong” (i.e. the same amino acid change as a previously established pathogenic 
variant, confirmed as de novo when there is no family history, or is associated with well-
established functional studies demonstrating a deleterious effect), “moderate” (i.e. absence from 
large control populations like ExAC), or “supporting” (i.e. multiple lines of computational 
evidence predicting a deleterious effect) evidence for pathogenicity. Points earned in each 
category are combined in a variety of ways to reach a final variant classification.  
Recently, following interrogation of 77 cardiac channelopathy/cardiomyopathy genes, 
Lahrouchi and colleagues reported a yield of ACMG guideline predicated “pathogenic” / ”likely 
pathogenic” variants in 13% of their mostly European decent (88%) cohort of 302 SUDY cases 
without structural heart disease or nonspecific cardiovascular changes
15
.  Congruent with a 
phenotype of negative-autopsy and suspected sudden cardiac arrhythmia death, 85% of the 
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“pathogenic” / ”likely pathogenic” variants identified by Lahrochi and colleagues were in major 
cardiac channelopathy-susceptibility genes (i.e. KCNQ1, KCNH2, SCN5A, and RYR2)
15
.   
While using their own interpretation for labeling variants as ‘pathogenic’ or ‘likely 
pathogenic’, Bagnall and colleagues reported finding such variants in 27% of their SUDY cases5.  
However, when applying the ACMG guideline criteria to their identified variants, this yield 
decreases to only 7.1% (8/113).  In fact, based on the ACMG guidelines, 28 of their 36 
‘pathogenic’ or ‘likely pathogenic’ variants would be demoted to a VUS.  The difference in 
variant interpretation stems largely from the over-calling of missense variants as being ‘likely 
pathogenic’.  In their study, missense variants with a MAF < 0.1% that were predicted to be 
damaging by at least 2 out of 3 in silico tools (SIFT, Polyphen, Mutation Taster) and involving 
conserved nucleotides (GREP score ≥ 2) were considered as ‘likely pathogenic’5. However, 
according to ACMG, this level of evidence alone would be deemed insufficient to promote a 
variant to a “likely pathogenic” designation.  
Based on ACMG guideline criteria, 28% of our overall cohort hosted at least one 
“pathogenic” / “likely pathogenic” variant.  The yield of “pathogenic”/ “likely pathogenic” 
variants was about 30% for both the autopsy-negative and equivocal cases with cardiomyopathic 
findings at autopsy.  This reflects a 20% higher yield of ACMG guideline predicated variants in 
our cohort than what was observed in the phenotypically and demographically similar cohort 
investigated by Bagnall and colleagues
5
.   The large difference in yield may stem from 
differences in the next-generation sequencing platforms and bioinformatics-based variant 
annotation and analytical pipelines that were used as well our inclusion of 40 additional genes 
that were not included in the Bagnall study
5
.  In fact, 3 of our 25 (12%) cases had either a TTN 
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frameshift (2 cases) or NEBL splice-error (1 case) “likely pathogenic” variant.  However, these 
two genes were not included in the Bagnall study
5
. 
  However, while 28% of our SUDY cases hosted a “pathogenic” or “likely pathogenic” 
variant based on the ACMG guidelines, the decedent’s phenotype at autopsy was congruent with 
the genetic finding in only 14% of cases and therefore considered “clinically actionable”.  These 
“clinically actionable” pathogenic/ likely pathogenic variants have sufficient genotype-
phenotype evidence to warrant cascade genetic testing of surviving family members. However, 
other ultra-rare variants that don’t rise to our present consideration f “clinically actionable” 
might be deemed as nevertheless worthy of careful research/clinical-based investigations to see if 
the variant co-segregates with the disease phenotype which if it did, then those variants might be 
elevated to a “clinically actionable” status that would wa rant cascade genetic testing for future 
family members. 
Interestingly, three cardiomyopathy-associated genes variants that satisfied the ACMG 
guideline criteria for pathogenic or likely pathogenic designation based on being an “ultra-rare” 
and null variant (i.e. nonsense or splice-error) were identified in SUDY victims with no autopsy 
findings suggestive of a structurally abnormal heart. Although some cardiomyopathy-associated 
gene variants can provide a potentially lethal arrhythmic substrate prior to the development of 
overt cardiomyopathic changes, because these identified variants were not congruent with the 
observed phenotype, the designation of these variants, as ACMG guideline-predicated 
“pathogenic” or “likely pathogenic” variants, should be rendered with some residual skepticism.   
It is noteworthy that 1/3 of the ultra-rare variants identified were categorized as "needs 
further functional study."  These variants are potentially informative clinically given their 
presence in disease-associated genes and their ultra-rare status.  However, they currently lack 
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sufficient clinical evidence (i.e. co-segregation with disease phenotype) and research-based 
evidence (i.e. in vitro functional validation assay) to be put forward as a disease-causing, 
clinically relevant variant.     
CONCLUSIONS 
Despite 64% of this population-based cohort of consecutive, unrelated SUDY cases having ultra-
rare, nonsynonymous variants within sudden death-susceptibility genes, 28% had a variant 
classified as either “pathogenic” or “likely pathogenic” based on the ACMG guidelines. 
Furthermore, 14% of cases had a congruent genotype-phenotype correlation enabling the variant 
to be clinically actionable for cascade genetic testing of surviving family members. The 
substantial number of VUSs demonstrates the necessity for further standardizing the adjudication 
of putative pathogenic variants. While the current ACMG guidelines are useful, careful 
evaluation of the decedent’s autopsy findings and/or pre-mortem clinical phenotype remains 
critical before adjudicating a variant as the de initive cause of death in SUDY cases. The goal of 
these investigative studies is always to provide closure to families surrounding the loss of their 
loved one, but perhaps the only thing worse than no answer, is to give a false answer 
prematurely. 
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Table 1: SUDY Cohort Demographics   
Cases 25 
Age (years) 27.0 ± 5.7 
Male  17 (68%) 
Female 8 (32%) 
White  13 (52%) 
Black 12 (48%) 
Autopsy Negative 16 (64%) 
Equivocal  9 (36%) 
Equivocal Cardiomyopathy  6 (24%)  
Event: Unwitnessed 10 (40%) 
Event: Sleep 9 (36%) 
Event: Nonspecific  3 (12%) 
Event: Exertion/Auditory  3 (12%) 
Illicit drug use 6 (24%) 
Mental Illness  5 (20%) 
Arrhythmia or syncope 2 (8%) 
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Table 2:  SUDY Case Summary and Variant Adjudication 
Case Sex 
Age 
(years) 
Race 
Setting of 
SUDY 
Autopsy Findings 
Autopsy 
Classification 
Equivocal 
Cause 
Variant(s) 
Associated 
Disease(s) 
ACMG 
Criteria Met 
ACMG 
Classification 
Clinically Actionable?  
1 M 14 White Exertion Contraction band necrosis 
Autopsy 
negative  
- 
p.L567Q-SCN5A 
LQTS, BrS, 
DCM 
PS1, PS3, PS4, 
PM1, PM2, PP3 
Pathogenic  Yes 
p.N4763S-RYR2 CPVT, ACM PM1, PM2, PP2 Likely pathogenic  Yes 
p.Y332C-PDLIM3 DCM PM2 VUS No 
p.G28A-MYPN HCM, DCM PM2 VUS No 
2 M 19 Black Auditory 
Interventricular septum 
hypertrophy, right atrial 
enlargement with 
endocardial fibroelastosis, 
right ventricular elongated 
chordae 
Autopsy 
negative 
- p.S688P-PKP2 ACM PM2 VUS No 
3 F 19 White Unwitnessed None 
Autopsy 
negative  
- p.I591V-ACTN2 HCM, DCM PM2 VUS No 
4 F 19 White Sleep None 
Autopsy 
negative  
- - - - - - 
5 F 21 White Unwitnessed  None 
Autopsy 
negative  
- 
c.903+1G>A-
NEBL 
DCM PVS1, PM2 Likely pathogenic  No 
6 F 23 White Unwitnessed None Equivocal  
Possible drug 
toxicity  
- - - - - 
7 M 25 Black Sleep 
Thin LV wall (0.6cm), 
scattered hypertrophic 
myocytes 
Equivocal  Cardiomyopathy  p.K120T-KCNJ2 LQTS PM2 VUS No 
8 M 26 White Sleep None 
Autopsy 
negative  
- - - - - - 
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9 F 27 Black Nonspecific  
LV hypertrophy (1.8cm), 
LV posterior MI scarring 
Equivocal  
Ischemic 
cardiomyopathy  
p.R783H-MYH7 HCM, DCM 
PS1, PM1, 
PM2, PM5, 
PM6, PP2, PP4 
Pat ogenic  Yes 
p.V27236fs-TTN HCM, DCM PVS1, PM2 Likely pathogenic  Yes 
p.V190M-JUP ACM PM2 VUS - 
10 F 27 Black Unwitnessed 
Interstitial and perivascular 
fibrosis  
Autopsy 
negative 
- p.R25W-LAMP2 HCM PM2 VUS - 
11 M 27 Black Unwitnessed None Equivocal  
Possible 
sarcoidosis  
- - - - - 
12 M 27 White Sleep 
Focal perivascular fibrosis, 
probe-patent foramen 
ovale 
Autopsy 
negative  
- p.K942X-MYH6 HCM, DCM PVS1, PM2 Likely pathogenic  No 
13 M 28 Black Unwitnessed  
Focal myocyte 
hypertrophy  
Autopsy 
negative  
- p.E44Q-ILK DCM PM2 VUS No 
14 M 28 Black Unwitnessed 
Intraventricular septum 
hypertrophy (2.0cm) 
Equivocal Cardiomyopathy  p.A52P-MYOM1 HCM PM2 VUS No 
15 M 28 White Sleep 
Enlarged heart (610g), LV 
hypertrophy, enlarged 
tricuspid valve with 
abnormal chordae, fusion 
of aortic valve cusps, 
myocyte hypertrophy   
Equivocal  
Hypertrophic 
cardiomyopathy  
p.Y462S-RYR2 CPVT, ACM 
PM1, PM2, 
PM5, PP2 
Likely pathogenic  No 
p.R350Q-DES DCM 
PM1, PM2, 
PM5, PP2 
Likely pathogenic Yes 
16 M 29 Black Exertion  
Focal interstitial and 
perivascular fibrosis, 
myocyte nuclear 
hypertrophy 
Equivocal  
Excited delirium 
(schizophrenia) 
p.R1899H-MYH6 HCM, DCM PM2 VUS No  
17 M 29 Black Unwitnessed Subendocardial fibrosis 
Autopsy 
negative  
 p.Q1289X-DSP ACM 
PVS1, PM2, 
PP3 
Pathogenic  No 
- 
p.F1198L-
LAMA4 
DCM PM2 VUS No 
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 p.R3Q-CTF1 DCM PM2 VUS No 
18 M 29 White Unwitnessed 
Focal interstitial and 
perivascular fibrosis 
Equivocal  Cardiomyopathy  - - - - - 
19 M 29 White Sleep None 
Autopsy 
negative  
- p.G8D-SCN4B LQTS PM2 VUS No 
20 M 30 Black Sleep None 
Autopsy 
negative  
- - - - - - 
21 M 30 White Nonspecific None 
Autopsy 
negative  
- - - - - - 
22 M 30 White Unwitnessed  None 
Autopsy 
negative  
- - - - - - 
23 F 36 White Sleep 
Interstitial fibrosis, 
myocyte hypertrophy  
Autopsy 
negative  
- 
p.D22167fs-TTN HCM, DCM PVS1, PM2 Likely pathogenic  Yes 
p.V585M-
CACNA1C 
BrS, LQTS PM2 VUS No  
24 M 37 Black Sleep 
Enlarged heart (625g), LV 
hypertrophy (2.2cm), 
intraventricular septum 
hypertrophy (2.0cm), 
myocyte fibrosis and 
disarray 
Equivocal  
 p.W427R-RBM20 DCM PM2 VUS No  
Hypertrophic 
cardiomyopathy   
p.A531T-MYLK2 HCM PM2 VUS No 
 p.P486L-TBX1 HCM PM2, PP2 VUS No 
25 F 39 Black Nonspecific  
Tunneling of LAD (1mm 
deep) 
Autopsy 
negative  
- - - - - - 
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FIGURES 
Figure 1:   Yield of Ultra-Rare Nonsynonymous Variants and ACMG Guideline-Designated 
Pathogenic/Likely Pathogenic Variants Identified in Sudden Unexplained Death in the Young -  Shown is 
a bar graph indicating the percent yield of “ultra-rare” (minor allele frequency < 0.005%) nonsynonymous 
variants and ACMG guideline predicated “pathogenic” / “likely pathogenic” variants detected among 99 cardiac 
channelopathy/cardiomyopathy/SUDEP-associated genes for our overall cohort and the ethnic-specific (white 
or black), autopsy negative, and autopsy equivocal subsets.  
 
Figure 2:  White Case: Control Comparative Analysis of Ultra-Rare Nonsynonymous Variants and 
ACMG Guideline-Designated Pathogenic/Likely Pathogenic Variants 
Shown is a bar graph indicating the percent yield of “ultra-rare” (minor allele frequency < 0.005%) 
nonsynonymous (NS) variants and ACMG guideline predicated “pathogenic” / “likely pathogenic” variants 
detected among 99 cardiac channelopathy/cardiomyopathy/SUDEP-associated genes for white sudden 
unexplained death in the young cases (n=13) and European white controls (n=973).  
 
Figure 3:  Variant Interpretation Flow-Diagram – Shown is a flow-diagram algorithm used to determine 
whether an identified “ultra-rare” non-synonymous variant was considered “clinically actionable”, “needs 
further functional study”, or presumed “likely benign”.   Numbers in parenthesis indicate number of variants. 
*Major genes include KCNQ1, KCNH2, SCN5A, RYR2, MYH7, and MYBPC3. Minor genes include all other 
genes in 99 gene panel. VUS = variant of uncertain significance.    
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